Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

被引：7

作者：

Navitski, Anastasia ^{[1
]}

Al-Rawi, Duaa H. ^{[2
]}

Liu, Ying ^{[2
,3
,4
]}

Rubinstein, Maria M. ^{[2
,3
]}

Friedman, Claire F. ^{[2
,3
]}

Rampal, Raajit K. ^{[3
,5
]}

Mandelker, Diana L. ^{[4
]}

Cadoo, Karen ^{[6
]}

O'Cearbhaill, Roisin E. ^{[2
,3
]}

机构：

[1] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10065 USA

[3] Weill Cornell Med Coll, Dept Med, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, 1275 York Ave, New York, NY 10065 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10065 USA

[6] Trinity Coll Dublin, St Jamess Hosp, Trinity St Jamess Canc Inst, Dublin, Ireland

来源：

GYNECOLOGIC ONCOLOGY REPORTS | 2021年 / 38卷

关键词：

Ovarian cancer; BRCA mutation; PARP inhibitors; Myelodysplastic syndrome; Acute myeloid leukemia;

D O I：

10.1016/j.gore.2021.100873

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are rare toxicities of PARPi. We describe three patients with germline BRCA-associated (gBRCA+) HGOC and alterations in AML driver genes. Although none evidenced overt hematologic malignancy, PARPi maintenance was cautiously considered given the potential risk of MDS/AML. A better understanding of the role of clonal hematopoiesis in the subsequent development of PARPi-associated MDS/AML will improve management of this patient population.

引用

页数：5

共 15 条

[1]

Bolton KL, 2020, J CLIN ONCOL, V38

[2] Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies [J].

Bowman, Robert L. ;

Busque, Lambert ;

Levine, Ross L. .

CELL STEM CELL, 2018, 22 (02) :157-170

[3] Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment [J].

Coorens, Tim H. H. ;

Collord, Grace ;

Lu, Wanhua ;

Mitchell, Emily ;

Ijaz, Jannat ;

Roberts, Thomas ;

Oliver, Thomas R. W. ;

Burke, G. A. Amos ;

Gattens, Michael ;

Dickens, Emmy ;

Nangalia, Jyoti ;

Tischkowitz, Marc ;

Anderson, John ;

Shlien, Adam ;

Godfrey, Anna L. ;

Murray, Matthew J. ;

Behjati, Sam .

BLOOD, 2021, 137 (21) :2992-2997

[4] Targeting FLT3 mutations in AML: review of current knowledge and evidence [J].

Daver, Naval ;

Schlenk, Richard F. ;

Russell, Nigel H. ;

Levis, Mark J. .

LEUKEMIA, 2019, 33 (02) :299-312

[5] Mutations in AML: prognostic and therapeutic implications [J].

DiNardo, Courtney D. ;

Cortes, Jorge E. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :348-355

[6] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Gonzalez-Martin, A. ;

Pothuri, B. ;

Vergote, I. ;

DePont Christensen, R. ;

Graybill, W. ;

Mirza, M. R. ;

McCormick, C. ;

Lorusso, D. ;

Hoskins, P. ;

Freyer, G. ;

Baumann, K. ;

Jardon, K. ;

Redondo, A. ;

Moore, R. G. ;

Vulsteke, C. ;

O'Cearbhaill, R. E. ;

Lund, B. ;

Backes, F. ;

Barretina-Ginesta, P. ;

Haggerty, A. F. ;

Rubio-Perez, M. J. ;

Shahin, M. S. ;

Mangili, G. ;

Bradley, W. H. ;

Bruchim, I. ;

Sun, K. ;

Malinowska, I. A. ;

Li, Y. ;

Gupta, D. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402

[7] TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors [J].

Maifrede, Silvia ;

Bac Viet Le ;

Nieborowska-Skorska, Margaret ;

Golovine, Konstantin ;

Sullivan-Reed, Katherine ;

Dunuwille, Wangisa M. B. ;

Nacson, Joseph ;

Hulse, Michael ;

Caruso, Lisa Beatrice ;

Gazze, Zachary ;

Lian, Zhaorui ;

Padella, Antonella ;

Chitrala, Kumaraswamy ;

Bartholdy, Boris ;

Matlawska-Wasowska, Ksenia ;

Di Marcantonio, Daniela ;

Simonetti, Giorgia ;

Greiner, Georg ;

Sykes, Stephen M. ;

Valent, Peter ;

Paietta, Elisabeth M. ;

Fernandez, Hugo F. ;

Tallman, Martin S. ;

Litzow, Mark ;

Minden, Mark D. ;

Huang, Jian ;

Martinelli, Giovanni ;

Vassiliou, George S. ;

Tempera, Italo ;

Piwocka, Katarzyna ;

Johnson, Neil ;

Challen, Grant ;

Skorski, Tomasz .

BLOOD, 2020, 136

[8] Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection [J].

Martin, Jean-Edouard ;

Khalife-Hachem, Sabine ;

Grinda, Thomas ;

Kfoury, Maria ;

Garciaz, Sylvain ;

Pasquier, Florence ;

Vargaftig, Jacques ;

Uzunov, Madalina ;

Belhabri, Amine ;

Bertoli, Sarah ;

Auger, Nathalie ;

Saada, Veronique ;

Guillouf, Christel ;

Antony-Debre, Ileana ;

Rouleau, Etienne ;

Salviat, Flore ;

Caron, Olivier ;

Pautier, Patricia ;

Etienne, Gabriel ;

Vey, Norbert ;

Rosselli, Filippo ;

De Botton, Stephane ;

Leary, Alexandra ;

Marzac, Christophe ;

Micol, Jean-Baptiste .

BLOOD, 2020, 136

[9] Implications of Clonal Hematopoiesis for Precision Oncology [J].

Miller, Peter G. ;

Steensma, David P. .

JCO PRECISION ONCOLOGY, 2020, 4 :639-646

[10] Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Moore, K. ;

Colombo, N. ;

Scambia, G. ;

Kim, B. -G. ;

Oaknin, A. ;

Friedlander, M. ;

Lisyanskaya, A. ;

Floquet, A. ;

Leary, A. ;

Sonke, G. S. ;

Gourley, C. ;

Banerjee, S. ;

Oza, A. ;

Gonzalez-Martin, A. ;

Aghajanian, C. ;

Bradley, W. ;

Mathews, C. ;

Liu, J. ;

Lowe, E. S. ;

Bloomfield, R. ;

DiSilvestro, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) :2495-2505

← 1 2 →